Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

How much Sarepta can hope to earn from Elevidys is unclear due to its cost, $3 million, and that it's not a cure. Yet SRPT stock is surging.

The post Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost appeared first on InvestorPlace.

More From InvestorPlace

• The #1 AI Investment Might Be This Company You’ve Never Heard Of
• Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
• Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future”